ImmuPharma (LON:IMM) Trading Down 19.6% - Time to Sell?

Key Points

• ImmuPharma's share price plummeted 19.6% to GBX 11.98 ($0.16) amidst an increase in trading volume, with 29.5 million shares exchanged compared to an average of 8.4 million.
• The company reported a quarterly earnings loss of GBX (0.38) per share, with analysts predicting a negative EPS of -339 for the current fiscal year.
• ImmuPharma specializes in peptide-based therapeutics, with their lead product, Lupuzor™, aimed at treating Lupus and showing potential for other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was down 19.6% during trading on Wednesday . The stock traded as low as GBX 11.15 ($0.15) and last traded at GBX 11.98 ($0.16). Approximately 29,480,865 shares changed hands during trading, an increase of 249% from the average daily volume of 8,439,087 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Price Performance

The firm's 50 day moving average is GBX 4.28 and its 200 day moving average is GBX 3.27. The firm has a market cap of £62.47 million, a P/E ratio of -1,404.49 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.